CytomX Therapeutics

CytomX is unlocking the potential of antibody therapeutics in oncology by developing a novel therapeutic antibody class of highly targeted Probody therapeutics. The Company's Probody Platform allows to design drugs that selectively activate in the tumor microenvironment while reducing drug activity in healthy tissue and in circulation. This ability to localize therapeutic effects to the tumor reduces systemic toxicity, with potential for safer and more effective therapies for a broad array of validated and previously inaccessible oncology targets. Driven by a vision to transform patient lives, CytomX is an advancing multiple Probody cancer immunotherapies and Probody drug conjugates toward clinical investigation, while also applying its technology to bispecific T-cell engaging antibodies and ProCAR-NK cell therapies.
Company Growth (employees)
Type
Public
HQ
South San Francisco, US
Founded
2008
Size (employees)
78 (est)
Website
cytomx.com
CytomX Therapeutics was founded in 2008 and is headquartered in South San Francisco, US

CytomX Therapeutics Office Locations

CytomX Therapeutics has an office in South San Francisco
South San Francisco, US (HQ)
100 343 Oyster Point Blvd

CytomX Therapeutics Financials and Metrics

CytomX Therapeutics Financials

CytomX Therapeutics's revenue was reported to be $11.2 m in Q1, 2017
USD

Revenue (Q1, 2017)

11.2 m

Net income (Q1, 2017)

(8.3 m)

EBIT (Q1, 2017)

(8.6 m)

Market capitalization (19-Oct-2017)

738.9 m

Cash (31-Dec-2016)

104.6 m
CytomX Therapeutics's current market capitalization is $738.9 m.
USDFY, 2015FY, 2016

Revenue

7.7 m15 m

Revenue growth, %

95%

EBIT

(33.2 m)(59.6 m)

EBIT margin, %

(431%)(396%)
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

1.9 m1.8 m2.5 m2.8 m11.2 m

R&D expense

9.2 m13.4 m12.7 m13.3 m14.6 m

General and administrative expense

4.1 m5 m4.6 m5 m5.7 m

Operating expense total

13.2 m18.4 m17.4 m18.4 m20.3 m
USDFY, 2015FY, 2016

Cash

59.8 m104.6 m

Accounts Receivable

744 k2.2 m

Inventories

2.3 m3.9 m

Current Assets

189.8 m188.1 m
USDFY, 2015FY, 2016

Net Income

(35.4 m)(58.9 m)

Depreciation and Amortization

1.2 m1.7 m

Accounts Receivable

1.1 m(1.8 m)

Accounts Payable

2.9 m1.8 m
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(11.9 m)(16 m)(14.2 m)(14.7 m)(8.3 m)

Accounts Receivable

406 k316 k285 k240 k213 k

Accounts Payable

2.7 m5 m1.4 m517 k3.7 m
USDY, 2017

Revenue/Employee

143.3 k
Show all financial metrics

CytomX Therapeutics Operating Metrics

FY, 2016

Phase I Trials

1

Phase Preclinical

4

Patents (US)

13

Patents (foreign)

4
Show all operating metrics

CytomX Therapeutics Market Value History

Traffic Overview of CytomX Therapeutics

CytomX Therapeutics Online and Social Media Presence

CytomX Therapeutics Company Life and Culture

You may also be interested in